Lessons learned on Real-World Evidence to Inform Cancer Drug Funding Decisions in Canada

Date:

Thursday, 17 October 2019

Time:

10.00am – 11.00am

Venue:

Seminar Room 05-03K, Level 5
Tahir Foundation Building (MD1)
National University of Singapore
12 Science Drive 2, S(117549)

Synopsis:

Real-world evidence (RWE) is increasingly being considered during the pharmaceutical regulatory approval or funding process in multiple jurisdictions. In this presentation, we will present the findings of a Canadian qualitative study to highlight the potential challenges and barriers of using RWE for the purpose of informing cancer drug reimbursement decisions. We will then review a case study involving population-based comparative effectiveness, safety and cost-effectiveness analyses of a cancer drug to illustrate the potential challenges of conducting RWE and the lessons learned. We will finish with a description of a multi-year, multi-stakeholder initiative named the Canadian Real-world Evidence of Value for Cancer Drugs (CanREValue) collaboration, which aims to develop a framework to generate and use RWE to inform cancer drug reimbursement decisions in Canada.

CME and CPE points pending approval.

About the speaker:

Dr Kelvin Chan is a medical oncologist at the Sunnybrook Odette Cancer Centre, an associate professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He specialises in GI oncology and head and neck oncology.

As a clinical epidemiologist and biostatistician, Dr Chan’s research interests include health services research, health technology assessment, meta-analysis including network meta-analysis, cost-effectiveness analyses, and statistical methods research in health economics. He is the co-director of the Canadian Centre for Applied Research in Cancer Control (ARCC), funded by the Canadian Cancer Society (CCS).

Professionally, Dr Chan has an interest in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including the pan-Canadian Oncology Drug Review (pCODR), the Committee to Evaluate Drugs (CED) and the Ontario Steering Committee of Cancer Drugs (OSCCD). He is also the clinical lead for the Provincial Drug Reimbursement Programs (PDRP) at Cancer Care Ontario (CCO).